Jurkat tib 152

HEK-293T cells (gift from Dr. Myron Toews, University of Nebraska Medical Center, Omaha, VT, USA) were cultured in Dulbecco’s modified Eagle medium (DMEM; 10% fetal bovine serum, 2 mM L-glutamine, 1% pen-strep, and 0.2% normocin) were added at 37 °C in a 5% CO₂ atmosphere. Puromycin (2 µg/mL) was used as a selective antibiotic when required. Cells were passaged after reaching 95% confluency. Daudi (#CCL-213) and Jurkat (TIB-152) cells were purchased from ATCC and cultured in RPMI 1640 medium at 37 °C in a humidified 5% CO₂ atmosphere. The RPMI 1640 solution was supplemented with 25 mM D-glucose, 18 mM sodium bicarbonate, 10 mM HEPES, 1 mM sodium pyruvate, 10% fetal bovine serum, and 1% pen-strep (pH 7.4). Passaging of cells (at 1 × 10⁵ cells/mL) was carried out by centrifugation at 126 × g, 8 min, and resuspending the pellet in fresh media or by directly adding cells (at 1 × 10⁵ cells/mL) to fresh media at 20% volume.

THP-1 (TIB-202), Jurkat (TIB-152), and Raji (CCL-86) cells were purchased from ATCC (Manassas, VA, USA). The cells were maintained in a RPMI1640 medium (Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 10% FBS and 1% penicillin-streptomycin (Gibco, Life Technologies, Carlsbad, CA, USA) in 5% CO₂ at 37 °C.

MCF10ADCIS.com cells were generously provided by Fred Miller (Karmanos Cancer Institute, Detroit, MI, USA) and cultured following the provider’s recommendations. Jurkat (TIB-152) and DU4475 (HTB123) cell lines were purchased from ATCC. Cell line identity was confirmed by short tandem repeats (STR) analysis and the cells were regularly tested for mycoplasma (Venor GeM Mycoplasma Detection Kit, Sigma). Fresh normal and neoplastic breast tissue specimens were collected at Harvard-affiliated hospitals, at John Hopkins University School of Medicine, Baylor-Charles A. Sammons Cancer Center, Hellen Diller Family Comprehensive Cancer Center, Washington University School of Medicine, University of Michigan, Sutter Roseville Medical Center, Seoul National University using protocols approved by the Institutional Review Board at each institution. Tissue samples at Dana-Farber Cancer Institute were collected under Dana-Farber Harvard Cancer Center (DF/HCC) Institutional Review Board (IRB) protocol #93-085 following written informed consent and used in the lab in compliance with DF/HCC IRB protocol #14-400 approved for the use of de-identified tissue samples. The study is compliant with all relevant ethical regulations regarding research involving human participants. Samples were de-identified prior to transport to the laboratory.

Human colon cancer HCT116 (CCL-247) and Jurkat (TIB-152) cell lines were obtained from American Type Culture Collection (ATTC). The human MDA-MB-231 breast cancer cell line was a kind gift of Dr Patrick Legembre (Rennes, France). Jurkat-deficient for FADD or Caspase-8 was provided by Dr Juo and Blenis [35 (link),36 (link)]. HCT116 and MDA-MB-231 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM). Jurkat cells were grown in RPMI1640 medium. Both media were supplemented with 4.5 g/L of glucose, 4 mmol/L of L-glutamine, and 10% heat-inactivated fetal calf serum (FCS). Cells were maintained in 5% CO₂ at 37 °C.

HCT116 cells (RCB2979) [27 (link)] derived from human colorectal adenocarcinoma were obtained from the RIKEN cell bank (Ibaraki, Japan) and cultured in Dulbecco’s modified Eagle’s media supplemented with 10% fetal bovine serum. SW1116 (CCL-233) and SW480 (CCL-228), established from human colorectal adenocarcinoma, NCI-H226 (CRL-5826) [28 (link)], established from human mesothelioma, and Jurkat (TIB-152), established from human T cell leukemia, were provided from the American Type Culture Collection (Manassas, VA, USA), and cultured in RPMI-1640 medium supplemented with 10% fetal calf serum. ERC/mesothelin-specific mouse monoclonal antibody, 22A31, was established in our laboratory as previously described [29 (link)]. Normal mouse IgG1κ (MOPC-21, M969) was purchased from Sigma (St. Louis, MO, USA). Anti-human-specific Ki-67 antigen monoclonal antibody (clone MIB-1, M7240) was purchased from Dako (Glostrup, Denmark). Anti-cleaved caspase-3 (Asp175) antibody (#9661) was purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-FAS antibody (CH-11) was purchased from MBL life sciences (Tokyo, Japan).

Mouse colon carcinoma cell line CT26.CL25 (CRL-2639), human colon carcinoma cell lines SW620 (CCL-227), HT29 (HTB-38), COLO 205 (CCL-222) and Caco-2 (HTB-37), human neutrophilic promyeloblast cell line HL-60 (CCL-240), human monocyte/macrophage cell line THP-1 (TIB-202) and human lymphoblast cell line Jurkat (TIB-152) were purchased from American Type Culture Collection (ATCC, Manassas, VA). RPMI 1640 and Eagle's minimal essential medium (MEM) was obtained from Mediatech, Inc. (Manassas, VA). Macoy’s 5A modified medium was purchased from Sigma (St. Louis, MO). Fetal bovine serum (FBS) was from EQUITECH-BIO Inc. (Kerrville, TX). Penicillin-streptomycin stock was purchased from Lonza Rockland, Inc. (Allendale, NJ). Lipopolysaccharides from Escherichia coli O111:B4 was purchased from Sigma. Phycoerythrin (PE) conjugated antibodies targeting CD4 (H129.19), CD8b (YTS156.7.7), CD19 (6D5), dendritic cells (DCs) marker (33D1), LY6G (1A8), CD68 (FA-11) and mouse IgG1, κ isotype (MOPC-21) were purchased from BioLegend (San Diego, CA). OxPAPC (TLR2 and TLR4 inhibitor) and Polymyxin B (TLR4 inhibitor) were from InvitroGen (San Diego, CA).